Journey Medical Corporation DERM Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Accutane | $3.31M+8.2% | $3.06M+10.7% | $2.77M-18.4% | $3.4M-7.1% | $3.66M-5.6% | |
| Emrosi | $6.25M+25.1% | $5M+2.3% | $4.88M+74.7% | $2.8M+35.0% | $2.07M— | |
| Foam Franchise Products Amzeeq Zilxi | $1.05M-44.3% | $1.89M+43.9% | $1.31M+15.4% | $1.14M-25.6% | $1.53M-21.7% | |
| Other Legacy | $277K-51.8% | $575K-18.0% | $701K-4.6% | $735K+1.1% | $727K-35.0% | |
| Qbrexza | $5.03M-9.3% | $5.54M-24.7% | $7.36M+5.9% | $6.95M+34.6% | $5.16M-9.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Journey Medical Corporation break its business down?
- Journey Medical Corporation (DERM) reports revenue by product across 5 parts — Accutane, Emrosi, Foam Franchise Products Amzeeq Zilxi, Other Legacy and Qbrexza. Each is extracted from the segment footnotes and tracked over time.
- Where does Journey Medical Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Journey Medical Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
